{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:10:30Z","timestamp":1788909030963,"version":"build-2803163510"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1097\/md.0000000000009380","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T13:49:23Z","timestamp":1515592163000},"page":"e9380","source":"Crossref","is-referenced-by-count":41,"title":["Association of BRCA1\/2 mutations with ovarian cancer prognosis"],"prefix":"10.1097","volume":"97","author":[{"given":"Yong-Wen","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210309","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"key":"R2-8-20210309","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"R3-8-20210309","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"R4-8-20210309","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"R5-8-20210309","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","article-title":"Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program","volume":"94","author":"Brose","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R6-8-20210309","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"key":"R7-8-20210309","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12905-014-0150-5","article-title":"Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers","volume":"14","author":"Marchetti","year":"2014","journal-title":"BMC Womens Health"},{"key":"R8-8-20210309","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"key":"R9-8-20210309","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdq628","article-title":"Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients","volume":"22","author":"Vencken","year":"2011","journal-title":"Ann Oncol"},{"key":"R10-8-20210309","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/IGC.0000000000000247","article-title":"BRCA1\/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer","volume":"24","author":"Rudaitis","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"R11-8-20210309","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/annonc\/mdq577","article-title":"Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity","volume":"22","author":"Gallagher","year":"2011","journal-title":"Ann Oncol"},{"key":"R12-8-20210309","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2007.11.6905","article-title":"Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer","volume":"26","author":"Chetrit","year":"2008","journal-title":"J Clin Oncol"},{"key":"R13-8-20210309","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cancergen.2012.01.008","article-title":"Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival","volume":"205","author":"Liu","year":"2012","journal-title":"Cancer Genet"},{"key":"R14-8-20210309","first-page":"658","article-title":"Overall survival in BRCA-associated ovarian cancer: case-control study of an Italian series","volume":"31","author":"Artioli","year":"2010","journal-title":"Eur J Gynaecol Oncol"},{"key":"R15-8-20210309","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2015.11.009","article-title":"Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status","volume":"140","author":"Kotsopoulos","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R16-8-20210309","first-page":"551","article-title":"\u2019BRCAness\u2019 and its implications for platinum action in gynecologic cancer","volume":"34","author":"Muggia","year":"2014","journal-title":"Anticancer Res"},{"key":"R17-8-20210309","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"R18-8-20210309","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"R19-8-20210309","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"R20-8-20210309","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/sim.1303","article-title":"Aggregate data meta-analysis with time-to-event outcomes","volume":"21","author":"Williamson","year":"2002","journal-title":"Stat Med"},{"key":"R21-8-20210309","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ygyno.2015.12.027","article-title":"BRCA1\/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study","volume":"140","author":"Harter","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R22-8-20210309","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13048-016-0227-x","article-title":"BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study","volume":"9","author":"Unni","year":"2016","journal-title":"J Ovarian Res"},{"key":"R23-8-20210309","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/IGC.0000000000000086","article-title":"The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer","volume":"24","author":"Safra","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"R24-8-20210309","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ygyno.2012.03.006","article-title":"BRCA1\/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer","volume":"125","author":"Dann","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R25-8-20210309","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ygyno.2012.05.001","article-title":"Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma","volume":"126","author":"Hyman","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R26-8-20210309","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ygyno.2011.08.032","article-title":"A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer","volume":"123","author":"Adams","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R27-8-20210309","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2011.07.019","article-title":"Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers","volume":"123","author":"Hyman","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R28-8-20210309","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ygyno.2010.12.354","article-title":"Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations","volume":"121","author":"Lacour","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R29-8-20210309","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/1535-7163.MCT-11-0272","article-title":"BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin","volume":"10","author":"Safra","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"R30-8-20210309","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"key":"R31-8-20210309","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J Clin Oncol"},{"key":"R32-8-20210309","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"BRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Tan","year":"2008","journal-title":"J CLin Oncol"},{"key":"R33-8-20210309","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10689-006-9112-x","article-title":"Improved survival in BRCA2 carriers with ovarian cancer","volume":"6","author":"Pal","year":"2007","journal-title":"Fam Cancer"},{"key":"R34-8-20210309","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ygyno.2005.10.034","article-title":"BRCA1 promoter methylation predicts adverse ovarian cancer prognosis","volume":"101","author":"Chiang","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R35-8-20210309","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/cncr.21276","article-title":"Prognostic impact of BRCA1 pathogenic and BRCA1\/BRCA2 unclassified variant mutations in patients with ovarian carcinoma","volume":"104","author":"Majdak","year":"2005","journal-title":"Cancer"},{"key":"R36-8-20210309","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/cncr.11310","article-title":"Improved survival in women with BRCA-associated ovarian carcinoma","volume":"97","author":"Cass","year":"2003","journal-title":"Cancer"},{"key":"R37-8-20210309","first-page":"1196","article-title":"Failure of BRCA1 dysfunction to alter ovarian cancer survival","volume":"8","author":"Buller","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R38-8-20210309","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1200\/JCO.2002.20.2.463","article-title":"Effect of BRCA mutations on the length of survival in epithelial ovarian tumors","volume":"20","author":"Ben David","year":"2002","journal-title":"J Clin Oncol"},{"key":"R39-8-20210309","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1053\/ejso.2000.1097","article-title":"Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations","volume":"27","author":"Ramus","year":"2001","journal-title":"Eur J Surg Oncol"},{"key":"R40-8-20210309","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0301-2115(01)00318-9","article-title":"Survival analysis in familial ovarian cancer, a case control study","volume":"98","author":"Zweemer","year":"2001","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R41-8-20210309","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"JAMA"},{"key":"R42-8-20210309","first-page":"868","article-title":"Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group","volume":"59","author":"Pharoah","year":"1999","journal-title":"Cancer Res"},{"key":"R43-8-20210309","first-page":"235","article-title":"Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1","volume":"4","author":"Aida","year":"1998","journal-title":"Clin Cancer Res"},{"key":"R44-8-20210309","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJM199611073351901","article-title":"Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1","volume":"335","author":"Rubin","year":"1996","journal-title":"N Engl J Med"},{"key":"R45-8-20210309","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1200\/JCO.1998.16.2.397","article-title":"Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden","volume":"16","author":"J\u00f3hannsson","year":"1998","journal-title":"J Clin Oncol"},{"key":"R46-8-20210309","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3332\/ecancer.2016.639","article-title":"Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival","volume":"10","author":"Biglia","year":"2016","journal-title":"Ecancermedicalscience"},{"key":"R47-8-20210309","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10689-016-9873-9","article-title":"Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis","volume":"15","author":"Sabatier","year":"2016","journal-title":"Fam Cancer"},{"key":"R48-8-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13053-015-0044-z","article-title":"Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients","volume":"14","author":"Synowiec","year":"2016","journal-title":"Hered Cancer Clin Pract"},{"key":"R49-8-20210309","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev.pathol.3.121806.151422","article-title":"Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment","volume":"4","author":"Venkitaraman","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"R50-8-20210309","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10689-005-2832-5","article-title":"BRCA1 and BRCA2: chemosensitivity, treatment outcomes, and prognosis","volume":"5","author":"Foulkes","year":"2006","journal-title":"Fam Cancer"},{"key":"R51-8-20210309","doi-asserted-by":"crossref","first-page":"23899","DOI":"10.1074\/jbc.C000276200","article-title":"The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin","volume":"275","author":"Bhattacharyya","year":"2000","journal-title":"J Biol Chem"},{"key":"R52-8-20210309","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"R53-8-20210309","doi-asserted-by":"crossref","first-page":"151750","DOI":"10.1155\/2010\/151750","article-title":"The emerging role of PARP inhibitors in the treatment of epithelial ovarian cancer","volume":"2010","author":"Gien","year":"2010","journal-title":"J Oncol"},{"key":"R54-8-20210309","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ygyno.2015.03.042","article-title":"A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation: An NRG Oncology\/Gynecologic Oncology Group study","volume":"137","author":"Coleman","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R55-8-20210309","doi-asserted-by":"crossref","first-page":"e95285","DOI":"10.1371\/journal.pone.0095285","article-title":"The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"key":"R56-8-20210309","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1097-2765(01)00175-7","article-title":"Role of BRCA2 in control of the RAD51 recombination and DNA repair protein","volume":"7","author":"Davies","year":"2001","journal-title":"Mol Cell"},{"key":"R57-8-20210309","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","article-title":"Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis","volume":"21","author":"Zhong","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R58-8-20210309","doi-asserted-by":"crossref","first-page":"285","DOI":"10.18632\/oncotarget.12306","article-title":"Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"R59-8-20210309","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1158\/1078-0432.CCR-14-2497","article-title":"Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer","volume":"21","author":"Candido-dos-Reis","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000009380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:49:00Z","timestamp":1620960540000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201801120-00008"}},"subtitle":["An updated meta-analysis"],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000009380","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}